APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Coagulation Factor Ⅷ

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Human Coagulation Factor Ⅷ Market Outlook and Growth Opportunities 2026

22 December 2025197 pages

Choose your research edition.

Industry ResearchHuman Coagulation Factor Ⅷ Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Coagulation Factor Ⅷ Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Human Coagulation Factor Ⅷ Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Coagulation Factor Ⅷ Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Coagulation Factor Ⅷ Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Human Coagulation Factor Ⅷ market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Human Coagulation Factor Ⅷ is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Human Coagulation Factor Ⅷ is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human Coagulation Factor Ⅷ is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Human Coagulation Factor Ⅷ market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Human Coagulation Factor Ⅷ market include Taibang Bio, Guangdong Shuanglin, Shanghai Laishi, GreenCross, Pfizer, Pfizer, Hualan Bio, Bayer and Baxter, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Human Coagulation Factor Ⅷ market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human Coagulation Factor Ⅷ and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Coagulation Factor Ⅷ revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Human Coagulation Factor Ⅷ market.

Human Coagulation Factor Ⅷ Segment by Company

Taibang Bio

Guangdong Shuanglin

Shanghai Laishi

GreenCross

Pfizer

Pfizer

Hualan Bio

Bayer

Baxter

Octapharma

Grifols

CSL Behring

Human Coagulation Factor Ⅷ Segment by Type

Recombinant Factor VIII

Human Factor VIII

Human Coagulation Factor Ⅷ Segment by Application

Relvent Bleeding Diseases

Hemophilia A

Human Coagulation Factor Ⅷ Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Human Coagulation Factor Ⅷ status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Human Coagulation Factor Ⅷ key companies, revenue, market share, and recent developments.

3. To split the Human Coagulation Factor Ⅷ breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Human Coagulation Factor Ⅷ market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Human Coagulation Factor Ⅷ significant trends, drivers, influence factors in global and regions.

6. To analyze Human Coagulation Factor Ⅷ competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Coagulation Factor Ⅷ market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Coagulation Factor Ⅷ and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Coagulation Factor Ⅷ.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human Coagulation Factor Ⅷ industry.

Chapter 3: Detailed analysis of Human Coagulation Factor Ⅷ company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Human Coagulation Factor Ⅷ in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Human Coagulation Factor Ⅷ in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Human Coagulation Factor Ⅷ Industry Trends Table 2. Human Coagulation Factor Ⅷ Industry Drivers Table 3. Human Coagulation Factor Ⅷ Industry Opportunities and Challenges Table 4. Human Coagulation Factor Ⅷ Industry Restraints Table 5. Global Human Coagulation Factor Ⅷ Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Human Coagulation Factor Ⅷ Revenue Share by Company (2021-2026) Table 7. Global Human Coagulation Factor Ⅷ Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Human Coagulation Factor Ⅷ Key Company Manufacturing Base & Headquarters Table 9. Global Human Coagulation Factor Ⅷ Company, Product Type & Application Table 10. Global Human Coagulation Factor Ⅷ Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Human Coagulation Factor Ⅷ by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Recombinant Factor VIII Table 15. Significant Companies of Human Factor VIII Table 16. Global Human Coagulation Factor Ⅷ Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Human Coagulation Factor Ⅷ Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Human Coagulation Factor Ⅷ Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Human Coagulation Factor Ⅷ Sales Value Share by Type (2021-2026) Table 20. Global Human Coagulation Factor Ⅷ Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Relvent Bleeding Diseases Table 22. Significant Companies of Hemophilia A Table 23. Global Human Coagulation Factor Ⅷ Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Human Coagulation Factor Ⅷ Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Human Coagulation Factor Ⅷ Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Human Coagulation Factor Ⅷ Sales Value Share by Application (2021-2026) Table 27. Global Human Coagulation Factor Ⅷ Sales Value Share by Application (2027-2032) Table 28. Global Human Coagulation Factor Ⅷ Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Human Coagulation Factor Ⅷ Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Human Coagulation Factor Ⅷ Sales Value Share by Region (2021-2026) Table 31. Global Human Coagulation Factor Ⅷ Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Human Coagulation Factor Ⅷ Sales Value Share by Region (2027-2032) Table 33. Global Human Coagulation Factor Ⅷ Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Human Coagulation Factor Ⅷ Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Human Coagulation Factor Ⅷ Sales Value Market Share by Country (2021-2026) Table 36. Global Human Coagulation Factor Ⅷ Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Human Coagulation Factor Ⅷ Sales Value Market Share by Country (2027-2032) Table 38. Taibang Bio Company Information Table 39. Taibang Bio Business Overview Table 40. Taibang Bio Human Coagulation Factor Ⅷ Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Taibang Bio Human Coagulation Factor Ⅷ Product Portfolio Table 42. Taibang Bio Recent Development Table 43. Guangdong Shuanglin Company Information Table 44. Guangdong Shuanglin Business Overview Table 45. Guangdong Shuanglin Human Coagulation Factor Ⅷ Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Guangdong Shuanglin Human Coagulation Factor Ⅷ Product Portfolio Table 47. Guangdong Shuanglin Recent Development Table 48. Shanghai Laishi Company Information Table 49. Shanghai Laishi Business Overview Table 50. Shanghai Laishi Human Coagulation Factor Ⅷ Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Shanghai Laishi Human Coagulation Factor Ⅷ Product Portfolio Table 52. Shanghai Laishi Recent Development Table 53. GreenCross Company Information Table 54. GreenCross Business Overview Table 55. GreenCross Human Coagulation Factor Ⅷ Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. GreenCross Human Coagulation Factor Ⅷ Product Portfolio Table 57. GreenCross Recent Development Table 58. Pfizer Company Information Table 59. Pfizer Business Overview Table 60. Pfizer Human Coagulation Factor Ⅷ Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Pfizer Human Coagulation Factor Ⅷ Product Portfolio Table 62. Pfizer Recent Development Table 63. Pfizer Company Information Table 64. Pfizer Business Overview Table 65. Pfizer Human Coagulation Factor Ⅷ Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Pfizer Human Coagulation Factor Ⅷ Product Portfolio Table 67. Pfizer Recent Development Table 68. Hualan Bio Company Information Table 69. Hualan Bio Business Overview Table 70. Hualan Bio Human Coagulation Factor Ⅷ Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Hualan Bio Human Coagulation Factor Ⅷ Product Portfolio Table 72. Hualan Bio Recent Development Table 73. Bayer Company Information Table 74. Bayer Business Overview Table 75. Bayer Human Coagulation Factor Ⅷ Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Bayer Human Coagulation Factor Ⅷ Product Portfolio Table 77. Bayer Recent Development Table 78. Baxter Company Information Table 79. Baxter Business Overview Table 80. Baxter Human Coagulation Factor Ⅷ Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Baxter Human Coagulation Factor Ⅷ Product Portfolio Table 82. Baxter Recent Development Table 83. Octapharma Company Information Table 84. Octapharma Business Overview Table 85. Octapharma Human Coagulation Factor Ⅷ Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Octapharma Human Coagulation Factor Ⅷ Product Portfolio Table 87. Octapharma Recent Development Table 88. Grifols Company Information Table 89. Grifols Business Overview Table 90. Grifols Human Coagulation Factor Ⅷ Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Grifols Human Coagulation Factor Ⅷ Product Portfolio Table 92. Grifols Recent Development Table 93. CSL Behring Company Information Table 94. CSL Behring Business Overview Table 95. CSL Behring Human Coagulation Factor Ⅷ Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. CSL Behring Human Coagulation Factor Ⅷ Product Portfolio Table 97. CSL Behring Recent Development Table 98. Research Programs/Design for This Report Table 99. Authors List of This Report Table 100. Secondary Sources Table 101. Primary Sources List of Figures Figure 1. Human Coagulation Factor Ⅷ Product Image Figure 2. Global Human Coagulation Factor Ⅷ Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Coagulation Factor Ⅷ Market Size (2021-2032) & (US$ Million) Figure 4. Global Human Coagulation Factor Ⅷ Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Recombinant Factor VIII Image Figure 8. Human Factor VIII Image Figure 9. Global Human Coagulation Factor Ⅷ Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Human Coagulation Factor Ⅷ Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Human Coagulation Factor Ⅷ Sales Value Share by Type (2021-2032) Figure 12. Relvent Bleeding Diseases Image Figure 13. Hemophilia A Image Figure 14. Global Human Coagulation Factor Ⅷ Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Human Coagulation Factor Ⅷ Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Human Coagulation Factor Ⅷ Sales Value Share by Application (2021-2032) Figure 17. Global Human Coagulation Factor Ⅷ Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Human Coagulation Factor Ⅷ Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Human Coagulation Factor Ⅷ Sales Value (2021-2032) & (US$ Million) Figure 20. North America Human Coagulation Factor Ⅷ Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Human Coagulation Factor Ⅷ Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Human Coagulation Factor Ⅷ Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Human Coagulation Factor Ⅷ Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Human Coagulation Factor Ⅷ Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Human Coagulation Factor Ⅷ Sales Value (2021-2032) & (US$ Million) Figure 26. South America Human Coagulation Factor Ⅷ Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Human Coagulation Factor Ⅷ Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Human Coagulation Factor Ⅷ Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Recombinant Factor VIII
  • Human Factor VIII
Applications
  • Relvent Bleeding Diseases
  • Hemophilia A
Companies covered
  • Taibang Bio
  • Guangdong Shuanglin
  • Shanghai Laishi
  • GreenCross
  • Pfizer
  • Pfizer
  • Hualan Bio
  • Bayer
  • Baxter
  • Octapharma
  • Grifols
  • CSL Behring

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Human Coagulation Factor Ⅷ Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Human Coagulation Factor Ⅷ Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Human Coagulation Factor Ⅷ Market Dynamics
  1. 2.1 Human Coagulation Factor Ⅷ Industry Trends
  2. 2.2 Human Coagulation Factor Ⅷ Industry Drivers
  3. 2.3 Human Coagulation Factor Ⅷ Industry Opportunities and Challenges
  4. 2.4 Human Coagulation Factor Ⅷ Industry Restraints
3 Human Coagulation Factor Ⅷ Market by Company
  1. 3.1 Global Human Coagulation Factor Ⅷ Company Revenue Ranking in 2025
  2. 3.2 Global Human Coagulation Factor Ⅷ Revenue by Company (2021-2026)
  3. 3.3 Global Human Coagulation Factor Ⅷ Company Ranking (2024-2026)
  4. 3.4 Global Human Coagulation Factor Ⅷ Company Manufacturing Base and Headquarters
  5. 3.5 Global Human Coagulation Factor Ⅷ Company Product Type and Application
  6. 3.6 Global Human Coagulation Factor Ⅷ Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Human Coagulation Factor Ⅷ Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Human Coagulation Factor Ⅷ Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Human Coagulation Factor Ⅷ Market by Type
  1. 4.1 Human Coagulation Factor Ⅷ Type Introduction
  2. 4.1.1 Recombinant Factor VIII
  3. 4.1.2 Human Factor VIII
  4. 4.2 Global Human Coagulation Factor Ⅷ Sales Value by Type
  5. 4.2.1 Global Human Coagulation Factor Ⅷ Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Human Coagulation Factor Ⅷ Sales Value by Type (2021-2032)
  7. 4.2.3 Global Human Coagulation Factor Ⅷ Sales Value Share by Type (2021-2032)
5 Human Coagulation Factor Ⅷ Market by Application
  1. 5.1 Human Coagulation Factor Ⅷ Application Introduction
  2. 5.1.1 Relvent Bleeding Diseases
  3. 5.1.2 Hemophilia A
  4. 5.2 Global Human Coagulation Factor Ⅷ Sales Value by Application
  5. 5.2.1 Global Human Coagulation Factor Ⅷ Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Human Coagulation Factor Ⅷ Sales Value by Application (2021-2032)
  7. 5.2.3 Global Human Coagulation Factor Ⅷ Sales Value Share by Application (2021-2032)
6 Human Coagulation Factor Ⅷ Regional Value Analysis
  1. 6.1 Global Human Coagulation Factor Ⅷ Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Coagulation Factor Ⅷ Sales Value by Region (2021-2032)
  3. 6.2.1 Global Human Coagulation Factor Ⅷ Sales Value by Region: 2021-2026
  4. 6.2.2 Global Human Coagulation Factor Ⅷ Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Human Coagulation Factor Ⅷ Sales Value (2021-2032)
  7. 6.3.2 North America Human Coagulation Factor Ⅷ Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Human Coagulation Factor Ⅷ Sales Value (2021-2032)
  10. 6.4.2 Europe Human Coagulation Factor Ⅷ Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Human Coagulation Factor Ⅷ Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Human Coagulation Factor Ⅷ Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Human Coagulation Factor Ⅷ Sales Value (2021-2032)
  16. 6.6.2 South America Human Coagulation Factor Ⅷ Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Human Coagulation Factor Ⅷ Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Human Coagulation Factor Ⅷ Sales Value Share by Country, 2025 VS 2032
7 Human Coagulation Factor Ⅷ Country-level Value Analysis
  1. 7.1 Global Human Coagulation Factor Ⅷ Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Human Coagulation Factor Ⅷ Sales Value by Country (2021-2032)
  3. 7.2.1 Global Human Coagulation Factor Ⅷ Sales Value by Country (2021-2026)
  4. 7.2.2 Global Human Coagulation Factor Ⅷ Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Human Coagulation Factor Ⅷ Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Human Coagulation Factor Ⅷ Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Human Coagulation Factor Ⅷ Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Taibang Bio
  2. 8.1.1 Taibang Bio Company Information
  3. 8.1.2 Taibang Bio Business Overview
  4. 8.1.3 Taibang Bio Human Coagulation Factor Ⅷ Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Taibang Bio Human Coagulation Factor Ⅷ Product Portfolio
  6. 8.1.5 Taibang Bio Recent Developments
  7. 8.2 Guangdong Shuanglin
  8. 8.2.1 Guangdong Shuanglin Company Information
  9. 8.2.2 Guangdong Shuanglin Business Overview
  10. 8.2.3 Guangdong Shuanglin Human Coagulation Factor Ⅷ Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Guangdong Shuanglin Human Coagulation Factor Ⅷ Product Portfolio
  12. 8.2.5 Guangdong Shuanglin Recent Developments
  13. 8.3 Shanghai Laishi
  14. 8.3.1 Shanghai Laishi Company Information
  15. 8.3.2 Shanghai Laishi Business Overview
  16. 8.3.3 Shanghai Laishi Human Coagulation Factor Ⅷ Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Shanghai Laishi Human Coagulation Factor Ⅷ Product Portfolio
  18. 8.3.5 Shanghai Laishi Recent Developments
  19. 8.4 GreenCross
  20. 8.4.1 GreenCross Company Information
  21. 8.4.2 GreenCross Business Overview
  22. 8.4.3 GreenCross Human Coagulation Factor Ⅷ Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GreenCross Human Coagulation Factor Ⅷ Product Portfolio
  24. 8.4.5 GreenCross Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Human Coagulation Factor Ⅷ Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Human Coagulation Factor Ⅷ Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Human Coagulation Factor Ⅷ Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Human Coagulation Factor Ⅷ Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Hualan Bio
  38. 8.7.1 Hualan Bio Company Information
  39. 8.7.2 Hualan Bio Business Overview
  40. 8.7.3 Hualan Bio Human Coagulation Factor Ⅷ Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Hualan Bio Human Coagulation Factor Ⅷ Product Portfolio
  42. 8.7.5 Hualan Bio Recent Developments
  43. 8.8 Bayer
  44. 8.8.1 Bayer Company Information
  45. 8.8.2 Bayer Business Overview
  46. 8.8.3 Bayer Human Coagulation Factor Ⅷ Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Bayer Human Coagulation Factor Ⅷ Product Portfolio
  48. 8.8.5 Bayer Recent Developments
  49. 8.9 Baxter
  50. 8.9.1 Baxter Company Information
  51. 8.9.2 Baxter Business Overview
  52. 8.9.3 Baxter Human Coagulation Factor Ⅷ Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Baxter Human Coagulation Factor Ⅷ Product Portfolio
  54. 8.9.5 Baxter Recent Developments
  55. 8.10 Octapharma
  56. 8.10.1 Octapharma Company Information
  57. 8.10.2 Octapharma Business Overview
  58. 8.10.3 Octapharma Human Coagulation Factor Ⅷ Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Octapharma Human Coagulation Factor Ⅷ Product Portfolio
  60. 8.10.5 Octapharma Recent Developments
  61. 8.11 Grifols
  62. 8.11.1 Grifols Company Information
  63. 8.11.2 Grifols Business Overview
  64. 8.11.3 Grifols Human Coagulation Factor Ⅷ Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Grifols Human Coagulation Factor Ⅷ Product Portfolio
  66. 8.11.5 Grifols Recent Developments
  67. 8.12 CSL Behring
  68. 8.12.1 CSL Behring Company Information
  69. 8.12.2 CSL Behring Business Overview
  70. 8.12.3 CSL Behring Human Coagulation Factor Ⅷ Revenue and Gross Margin (2021-2026)
  71. 8.12.4 CSL Behring Human Coagulation Factor Ⅷ Product Portfolio
  72. 8.12.5 CSL Behring Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst